Ultragenyx Pharmaceutical (RARE.US) shares experienced a severe sell-off during Monday's pre-market trading session. At the time of writing, the stock was down more than 42%, trading at $19.69. The catalyst for the plunge was the company's announcement that its investigational drug for a specific genetic bone disease failed to meet the primary efficacy endpoint in a late-stage clinical trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.